ŚWIĄTECZNA DARMOWA DOSTAWA od 20 grudnia do 8 stycznia! Zamówienia złożone w tym okresie wyślemy od 2 stycznia 2025. Sprawdź >
W zależności od oceny klinicznej czas antybiotykoterapii ciężkiego zapalenia płuc może zostać wydłużony do 14-21 dni, przykładem takiej sytuacji mogą być zakażenia wywołane przez Staphylococcus aureus lub pałeczki jelitowe Gram(–).
Piśmiennictwo
1. National Institute for Health and Care Excellence. NICE Guideline 191: Pneumonia: Diagnosis and management of community- and hospital-acquired pneumonia in adults. https://www.nice.org.uk/guidance/cg191. 2014.
2. Narodowy Program Ochrony Antybiotyków. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego 2010. http://www.antybiotyki.edu.pl/pdf/RekomendacjeA42009.pdf
3. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3):iii1-iii55.
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72.
5. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26(6):1138-80.
6. CAP Guideline Working Group. 2015 – Annotated BTS Guideline for the management of CAP in adults (2009) Summary of recommendations. https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/community-acquired-pneumonia-in-adults-guideline/annotated-bts-guideline-for-the-management-of-cap-in-adults-2014/.
7. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985;78(6b):32-7.
8. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of Community-Acquired Pneumonia in the Population of Four Municipalities in Eastern Finland. Am J Epidemiol 1993;137(9):977-88.
9. Janssens JP, Krause KH. Pneumonia in the very old. The Lancet infectious diseases 2004;4(2):112-24.
10. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164(6): 637-44.
11. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. Jama 1997;278(23):2080-4.
12. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-50.
13. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections. JAMA: The Journal of the American Medical Association 2009;302(10):1059-66.
14. Li H, Luo Y-F, Blackwell TS, et al. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrobial Agents and Chemotherapy 2011;55(12):5900-6.
15. Holmberg H, Bodin L, Jonsson I, et al. Rapid aetiological diagnosis of pneumonia based on routine laboratory features. Scand J Infect Dis 1990;22(5):537-45.
16. Demkow U. Diagnostyka immunologiczna i molekularna zakażeń dróg oddechowych. Pneumonol Alergol Pol 2011;79(6):446-53.
17. Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58(5):377-82.